Reconceptualizing Cancer Immunotherapy Based on Plant Production Systems

Hefferon, Kathleen

doi:10.4155/fsoa-2017-0018

Cited by 10 publications

(5 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some are already approved by the FDA for a clinical trial ( Table 1 ). This is due to the high production capacity, inexpensive large-scale cultivation process, low downstream processing requirements that can be grown under containment conditions, and avoidance of ethical issues associated with transgenic animals [ 11 , 28 ]. Currently, there are over a dozen FDA-approved mAbs, and as many as 700 therapeutic Abs may be under development.…”

Section: Methodsmentioning

confidence: 99%

Plant‐Produced Monoclonal Antibody as Immunotherapy for Cancer

Nessa

Kabir

2020

BioMed Research International

View full text Add to dashboard Cite

Plant-based products have expanded to include cancer immunotherapy, which has made great strides over recent years. Plants are considered inexpensive and facile production platforms for recombinant monoclonal antibody (mAb) due to the latest advancements and diversification of transgenic techniques. Current human biologics, including those based on mAbs produced by fermentation technologies using primarily mammalian cell cultures, have been replaced by plant-produced mAbs, which are cost effective, more scalable, speedy, versatile, and safer. Moreover, the use of animals for antibody production is always a question of ethical unambiguity, and the suitability of animal models for predicting the immunogenicity of therapeutic mAbs in humans and transposition of the immunogenic potential of therapeutic antibodies in animals to the human situation has no scientific rationale. Quite a few plant-based mAbs are approved for the treatment of cancer, ranging from tumors to hematological malignancies. This review focuses on the cutting-edge approaches for using plant-derived mAbs to suppress or prevent cancers. It also discusses the avenues taken to prevent infection by oncogenic viruses, solid tumors, lymphomas, and other cancerous conditions using mAbs. The review emphasizes the use of a plant-derived monoclonal antibody as a premier platform to combat cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Plant‐Produced Monoclonal Antibody as Immunotherapy for Cancer

Nessa

Kabir

2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…low cost, safety (low risk of contamination with animal pathogens), easy scale-up, stability, presence of metabolites, and ability to produce N-glycosylated proteins (Fahad et al, 2015;Yao et al, 2015;Łojewska et al, 2016;Lomonossoff and D'Aoust, 2016;Park and Wi, 2016;Xu et al, 2016;Buyel et al, 2017;Dirisala et al, 2017;Owczarek et al, 2019). Plant-based biologics have expanded to include cancer immunotherapy agents (Chen et al, 2016;Hefferon, 2017). Certain crucial factors should be considered to enhance the yield and quality of plant-produced biopharmaceuticals, namely the host plants, expression cassettes, subcellular localization, PTMs, and protein extraction and purification methodologies.…”

Section: Transgenic Plantsmentioning

confidence: 99%

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Tripathi

Shrivastava

2019

Front. Bioeng. Biotechnol.

402

243

View full text Add to dashboard Cite

Infectious diseases, along with cancers, are among the main causes of death among humans worldwide. The production of therapeutic proteins for treating diseases at large scale for millions of individuals is one of the essential needs of mankind. Recent progress in the area of recombinant DNA technologies has paved the way to producing recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents. Recombinant proteins for these applications are mainly produced using prokaryotic and eukaryotic expression host systems such as mammalian cells, bacteria, yeast, insect cells, and transgenic plants at laboratory scale as well as in large-scale settings. The development of efficient bioprocessing strategies is crucial for industrial production of recombinant proteins of therapeutic and prophylactic importance. Recently, advances have been made in the various areas of bioprocessing and are being utilized to develop effective processes for producing recombinant proteins. These include the use of high-throughput devices for effective bioprocess optimization and of disposable systems, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, Quality by Design, and process analytical technologies to achieve quality product with higher yield. This review summarizes recent developments in the bioprocessing of recombinant proteins, including in various expression systems, bioprocess development, and the upstream and downstream processing of recombinant proteins.

show abstract

“…Prepare influenza vaccine (Trombetta et al, 2022) and virus-like particle (Chen et al, 2022), produce large protein complex (Zhai et al, 2019), produce highly efficient avian recombinant adeno-associated virus (Wang et al, 2017;Mi et al, 2021), produce cytoplasmic protein and secreted protein (Lemaitre et al, 2019), and use purified protein to develop detection reagents Transgenic plants It has low costs, relatively safe, low risk of contamination with animal pathogens, easy amplification and good stability. It is insensitive to metabolites, and has the ability to modify N-glycosylation (Dirisala et al, 2017;Lomonossoff and D'Aoust, 2016;Lojewska et al, 2016;Park and Wi, 2016;Buyel et al, 2017;Owczarek et al, 2019) It is vulnerable to pesticides, herbicides and other pollution (Tripathi and Shrivastava, 2019) Produce tumor immunotherapy agents (Chen et al, 2016;Hefferon, 2017). Develop the influenza vaccine (Loh et al, 2017;Owczarek et al, 2019).…”

Section: Mammalian Cell Expression Systemmentioning

confidence: 99%

“…Develop the influenza vaccine (Loh et al, 2017;Owczarek et al, 2019). Synthesis of recombinases for disease therapy (Tekoah et al, 2015;Hefferon, 2017) Transgenic animals (Continued on following page)…”

Section: Mammalian Cell Expression Systemmentioning

confidence: 99%

1Progress, applications, challenges and prospects of protein purification technology

Hou

Liu

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Protein is one of the most important biological macromolecules in life, which plays a vital role in cell growth, development, movement, heredity, reproduction and other life activities. High quality isolation and purification is an essential step in the study of the structure and function of target proteins. Therefore, the development of protein purification technologies has great theoretical and practical significance in exploring the laws of life activities and guiding production practice. Up to now, there is no forthcoming method to extract any proteins from a complex system, and the field of protein purification still faces significant opportunities and challenges. Conventional protein purification generally includes three steps: pretreatment, rough fractionation, and fine fractionation. Each of the steps will significantly affect the purity, yield and the activity of target proteins. The present review focuses on the principle and process of protein purification, recent advances, and the applications of these technologies in the life and health industry as well as their far-reaching impact, so as to promote the research of protein structure and function, drug development and precision medicine, and bring new insights to researchers in related fields.

show abstract

Reconceptualizing Cancer Immunotherapy Based on Plant Production Systems

Cited by 10 publications

References 94 publications

Plant‐Produced Monoclonal Antibody as Immunotherapy for Cancer

Plant‐Produced Monoclonal Antibody as Immunotherapy for Cancer

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

1Progress, applications, challenges and prospects of protein purification technology

Contact Info

Product

Resources

About